DiaMedica Therapeutics Inc. (DMAC) Reports In-Line Q2 EPS

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.

You May Also Be Interested In

• Blackstone Mulls Pulling Plug on $3 Billion Stakes-for-Cash Deal - Bloomberg
• Raymond James on Monolithic Power Systems (MPWR): 'Full Steam Ahead'
• Mastercard may outperform Visa on revenue growth in 2027